Literature DB >> 19448065

Predicting the likelihood of additional nodal metastases in breast carcinoma patients with positive sentinel node biopsy.

Elvira Mustać1, Koviljka Matusan-Ilijas, Blazen Marijić, Miljenko Smokvina, Nives Jonjić.   

Abstract

Axillary lymph node dissection (ALND) is an important procedure in the staging of breast cancer patients. However, it is associated with a significant morbidity rate. In addition, using early diagnosis a high number of cases with negative lymph nodes can be identified. A lymph node defined as sentinel lymph node (SLN) would be the first to receive tumoral drainage. A less morbid but accurate staining procedure using mapping and SLN biopsy has been introduced. The aim of this study was to estimate the likelihood of additional disease in the axilla after SLN analysis. A total of 259 breast carcinomas and SLN biopsies followed by ALND were examined. The patient median age was 59 years, approximately 75% of them postmenopausal. Tumor size was 1.4 +/- 0.8 cm (almost 80% in pT1). SLNs were positive in 59 of 259 (22.8%) carcinomas, 30 (11.6%) with micrometastases (<2.0 mm) and 29 (11.2%) with metastases. Tumor size ( P = .004) and presence of lymphovascular invasion (LVI; P = .034) were found to be significant predictors of pathologically positive SLN. Following ALND, positive non-SLNs were present mostly in patients with metastasis >2 mm in SLN (P = .003), in carcinoma with higher nuclear grade ( P = .044), decreased estrogen receptor (ER; P = .042), and progesterone receptor (PR; P = .042). Finally, lymph node status (pN) following SLN and ALND was found to be significantly associated with tumor size ( P = .006), LVI (P = .037), PR (P = .023), and Her-2 status (P < .001). These results point to detailed analysis of primary tumor and SLN that may increase the precision of patient selection for further axillary surgery or radiotherapy.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19448065     DOI: 10.1177/1066896909332113

Source DB:  PubMed          Journal:  Int J Surg Pathol        ISSN: 1066-8969            Impact factor:   1.271


  6 in total

1.  Nine years of experience with the sentinel lymph node biopsy in a single Italian center: a retrospective analysis of 1,050 cases.

Authors:  Sergio Bernardi; Serena Bertozzi; Ambrogio P Londero; Francesco Giacomuzzi; Vito Angione; Cinzia Dri; Arnalda Carbone; Roberto Petri
Journal:  World J Surg       Date:  2012-04       Impact factor: 3.352

2.  Associated Features with Non-Sentinel Lymph Node Involvement in Early Stage Breast Cancer Patients who Have Positive Macrometastatic Sentinel Lymph Node.

Authors:  Hakan Ataş; Buket Altun Özdemir; Ebru Menekşe; Sabri Özden; Yunus Nadi Yüksek; Gül Dağlar
Journal:  Eur J Breast Health       Date:  2020-04-17

3.  Sentinel lymph node biopsy in breast cancer: predictors of axillary and non-sentinel lymph node involvement.

Authors:  Hakan Postacı; Baha Zengel; Ulkem Yararbaş; Adam Uslu; Nuket Eliyatkın; Göksever Akpınar; Fevzi Cengiz; Raika Durusoy
Journal:  Balkan Med J       Date:  2013-12-01       Impact factor: 2.021

4.  A new and simple predictive formula for non-sentinel lymph node metastasis in breast cancer patients with positive sentinel lymph nodes, and validation of 3 different nomograms in Turkish breast cancer patients.

Authors:  Levent Yeniay; Erdem Carti; Can Karaca; Osman Zekioglu; Ulkem Yararbas; Rasih Yilmaz; Murat Kapkac
Journal:  Breast Care (Basel)       Date:  2012-10       Impact factor: 2.860

5.  Tumor characteristics influencing non-sentinel lymph node involvement in clinically node negative patients with breast cancer.

Authors:  Gunay Gurleyik; Fugen Aker; Ali Aktekin; Abdullah Saglam
Journal:  J Breast Cancer       Date:  2011-06-18       Impact factor: 3.588

6.  Positive non-sentinel axillary lymph nodes in breast cancer with 1-2 sentinel lymph node metastases.

Authors:  Jianwei Zheng; Shuyan Cai; Huimin Song; Yunlei Wang; Xiaofeng Han; Haoliang Wu; Zhigang Gao; Fanrong Qiu
Journal:  Medicine (Baltimore)       Date:  2018-11       Impact factor: 1.817

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.